- Next-generation mRNA vaccines will be easier to use: Moderna CEO Yahoo Finance
- Moderna’s flu-Covid combo vaccine elicits ‘strong’ immune response in Phase 1/2 study, company says CNN
- What’s Going On With Moderna Stock Wednesday? – Moderna (NASDAQ:MRNA) Benzinga
- Moderna CEO on combo Covid, flu vaccine moving to next trial phase Yahoo Finance
- Self-amplifying mRNA seasonal influenza vaccines elicit mouse neutralizing antibody and cell-mediated immunity and protect ferrets | npj Vaccines Nature.com
- View Full Coverage on Google News
Tag Archives: MRNA
Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients | npj Vaccines – Nature.com
- Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients | npj Vaccines Nature.com
- Could baseline gut microbiota predict the immune responses elicited by COVID-19 vaccines? News-Medical.Net
- Antiviral peptide prevents SARS-CoV-2 from infecting host cells Medical Xpress
- Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2 Nature.com
- Intranasal vaccine shows promise against COVID variants in hamsters News-Medical.Net
- View Full Coverage on Google News
Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2 – Science
- Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2 Science
- Trial: Alternative COVID vaccine 75% cross-protective against symptomatic cases in previously infected University of Minnesota Twin Cities
- Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge | Signal Transduction and Targeted Therapy Nature.com
- New Omicron subvariant BA.2.86: A master of immune escape but not taking over yet News-Medical.Net
- Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial The Lancet
- View Full Coverage on Google News
Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history | Scientific Reports – Nature.com
- Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history | Scientific Reports Nature.com
- Exposure to lung-migrating helminth protects against murine SARS-CoV-2 infection through macrophage-dependent T cell activation Science
- Differences in SARS-CoV-2 specific humoral and cellular immune responses after contralateral and ipsilateral COVID-19 vaccination The Lancet
- Detection of different variants of SARS-CoV-2 RNA (genome) on inanimate surfaces in high-touch public environmental surfaces | Scientific Reports Nature.com
- Elevated binding and functional antibody responses to SARS-CoV-2 in infants versus mothers Nature.com
- View Full Coverage on Google News
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states – Science
- Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states Science
- PLSCR1 is a cell-autonomous defence factor against SARS-CoV-2 infection Nature.com
- IL-9 identified as contributor to viral spread and airway inflammation in COVID-19 News-Medical.Net
- Enhanced MHC-I Suppression In Omicron Variants: A Key Factor In Sustained Infection Forbes
- Antigen test swabs are comparable to nasopharyngeal swabs for sequencing of SARS-CoV-2 | Scientific Reports Nature.com
- View Full Coverage on Google News
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study – The Lancet
- Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study The Lancet
- Bivalent COVID-19 booster vaccine shown to be highly effective in reducing deaths and hospitalizations Medical Xpress
- Durability of Bivalent Boosters against Omicron Subvariants | NEJM nejm.org
- Pfizer bivalent vaccine reduces Covid-related death risk by 68 per cent in older people: Study The Financial Express
- New bivalent booster vaccines highly effective in reducing Covid deaths and hospitalisations, study finds Independent.ie
- View Full Coverage on Google News
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity – Nature.com
- SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity Nature.com
- ACE2: its diverse functions, relationship with SARS-CoV-2, and the implications for COVID-19 disease sequelae News-Medical.Net
- Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX – REVOLUTIOn trial The Lancet
- Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection Nature.com
- Evaluating SARS-CoV-2 bivalent booster vaccine against severe COVID-19 outcomes News-Medical.Net
- View Full Coverage on Google News
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients – Moderna Investor Relations
- Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients Moderna Investor Relations
- Moderna Pops On An FDA Boon For Its Merck-Tied Cancer Vaccine Investor’s Business Daily
- Moderna expands CRISPR gene editing research with ElevateBio partnership The Boston Globe
- Moderna’s combination skin cancer therapy receives FDA’s breakthrough tag Reuters
- Moderna taps Life Edit to develop next-gen gene therapies FierceBiotech
- View Full Coverage on Google News
Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023 | MMWR – CDC
- Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023 | MMWR CDC
- Chicago Department of Public Health revising at-home COVID 19 vaccine schedule; flu shot also offered WLS-TV
- Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age | NEJM nejm.org
- COVID-19 Bivalent Booster Vaccination Coverage and Intent to Receive Booster Vaccination Among Adolescents and Adults — United States, November–December 2022 | MMWR CDC
- US adds COVID-19 vaccine for babies to its immunisation schedule. Will Australia follow? SBS News
- View Full Coverage on Google News
An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination – Science
- An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination Science
- Reassuring Findings on Bivalent COVID Booster in Hemodialysis Patients Medpage Today
- Bivalent and monovalent mRNA boosters induce similar antibody response against Omicron subvariants News-Medical.Net
- Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose Science
- Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis | NEJM nejm.org
- View Full Coverage on Google News